Advertisement
Australia markets closed
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • AUD/USD

    0.6502
    +0.0013 (+0.20%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • OIL

    82.77
    -0.59 (-0.71%)
     
  • GOLD

    2,328.40
    -13.70 (-0.58%)
     
  • Bitcoin AUD

    102,150.98
    +298.09 (+0.29%)
     
  • CMC Crypto 200

    1,434.50
    +10.40 (+0.73%)
     

Is This Battered Growth Stock Still a Buy After Its Latest Stumble?

After reporting worse than anticipated second-quarter earnings on Aug. 8, shares of BioNTech (NASDAQ: BNTX) are tumbling, deepening the stock's decline to 65% over the last 12 months. The culprit is the biotech's lackluster sales of Comirnaty, its coronavirus vaccine developed in conjunction with Pfizer.